Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354467 · ClinicalTrials.gov registry record
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
A clinical trial of Acute Kidney Injury and Neonatal, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 148
- Enrollment target
- 2
- Study locations
NCT04354467 is a study of Acute Kidney Injury and Neonatal that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 148 participants, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04354467, a study of Acute Kidney Injury and Neonatal, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 148 participants
- Enrollment target
- 2
- Study locations
Study Summary
Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at UAB/Children's of Alabama Hospital, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypothesis of this NINJA NGAL study is that urine NGAL is highly sensitive to detect NTMx-associated AKI. UAB/Children's of Alabama is bringing urine NGAL measurement to the infants in the NICU to detect NTMX-associated AKI.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST urine neutrophil gelatinase -associated lipocalin
Study Locations (2)
Alabama
- Children's of Alabama - Birmingham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2023-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354467
The ClinicalTrials.gov registry entry for NCT04354467 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which urine neutrophil gelatinase -associated lipocalin is the first listed.
NCT04354467 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Ohio.
Frequently Asked Questions
What is clinical trial NCT04354467 about?
NCT04354467 is a clinical study titled "Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU". Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at UAB/Children's of Alabama Hospital, NTMx exposure was found to be potentially modifiable and...
What is the current status of trial NCT04354467?
This trial is currently completed. The enrollment target is 148 participants. The study started on 2019-01-28. Estimated completion is 2023-12-30.
What conditions does trial NCT04354467 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Neonatal, Nephrotoxicity.
What interventions are being tested in trial NCT04354467?
The interventions under investigation include: urine neutrophil gelatinase -associated lipocalin (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04354467?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04354467 being conducted?
This trial has 2 study locations across Alabama, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.